A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 10, Status: Authorised
2019
Case Medical Research
Preserved Fulltext
